DTG + 3TC FDC

DRUG2 trials

Sponsors

ViiV Healthcare, Chungnam National University Hospital

Conditions

HIVHIV Infections

Phase 3

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

CompletedNCT03682848

ViiV HealthcareHIV Infections

Start: 2019-05-06End: 2025-05-22Updated: 2025-12-09

Unknown Phase

Efficacy and Safety of DTG/3TC in Treatment-naïve HIV-1 Infected Patients

Enrolling by invitationNCT06928090

Chungnam National University HospitalHIV

Start: 2025-01-24End: 2027-01-30Target: 200Updated: 2025-04-15

Related Papers

Efficacy and Safety of the Two-Drug Regimen Dolutegravir–Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b Trial

JAIDS Journal of Acquired Immune Deficiency Syndromes2025-02-24